ZA201309295B - Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains - Google Patents

Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains

Info

Publication number
ZA201309295B
ZA201309295B ZA2013/09295A ZA201309295A ZA201309295B ZA 201309295 B ZA201309295 B ZA 201309295B ZA 2013/09295 A ZA2013/09295 A ZA 2013/09295A ZA 201309295 A ZA201309295 A ZA 201309295A ZA 201309295 B ZA201309295 B ZA 201309295B
Authority
ZA
South Africa
Prior art keywords
predicting
techniques
detecting
variable domains
single variable
Prior art date
Application number
ZA2013/09295A
Other languages
English (en)
Inventor
Judith Baumeister
Carlo Boutton
Veerle Snoeck
Marie-Paule Lucienne Armanda Bouche
Marie- Ange Buyse
Stephanie Staelens
Original Assignee
Ablynx Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47423024&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201309295(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/EP2011/067132 external-priority patent/WO2012042026A1/en
Priority claimed from PCT/EP2012/061304 external-priority patent/WO2012175400A1/en
Application filed by Ablynx Nv filed Critical Ablynx Nv
Publication of ZA201309295B publication Critical patent/ZA201309295B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
ZA2013/09295A 2011-06-23 2013-12-10 Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains ZA201309295B (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161500360P 2011-06-23 2011-06-23
US201161500464P 2011-06-23 2011-06-23
US201161541368P 2011-09-30 2011-09-30
PCT/EP2011/067132 WO2012042026A1 (en) 2010-09-30 2011-09-30 Biological materials related to c-met
US13/435,567 US8703135B2 (en) 2010-09-30 2012-03-30 Biological materials related to c-Met
PCT/EP2012/061304 WO2012175400A1 (en) 2011-06-23 2012-06-14 Serum albumin binding proteins
PCT/EP2012/062251 WO2012175741A2 (en) 2011-06-23 2012-06-25 Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains

Publications (1)

Publication Number Publication Date
ZA201309295B true ZA201309295B (en) 2015-01-28

Family

ID=47423024

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2013/09295A ZA201309295B (en) 2011-06-23 2013-12-10 Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains

Country Status (23)

Country Link
US (11) US20180009888A9 (OSRAM)
EP (1) EP2723769B2 (OSRAM)
JP (6) JP6258199B2 (OSRAM)
KR (7) KR102246924B1 (OSRAM)
CN (5) CN104203975B (OSRAM)
AU (7) AU2012273929B2 (OSRAM)
BR (3) BR112013032145B1 (OSRAM)
CA (3) CA3142288A1 (OSRAM)
DK (1) DK2723769T4 (OSRAM)
ES (1) ES2622006T5 (OSRAM)
HU (1) HUE031828T2 (OSRAM)
IL (4) IL250396B (OSRAM)
IN (1) IN2014CN00373A (OSRAM)
LT (1) LT2723769T (OSRAM)
MX (2) MX350074B (OSRAM)
NZ (1) NZ780183A (OSRAM)
PH (7) PH12022550310A1 (OSRAM)
PL (1) PL2723769T5 (OSRAM)
PT (1) PT2723769T (OSRAM)
RU (1) RU2700630C2 (OSRAM)
SG (4) SG194982A1 (OSRAM)
WO (1) WO2012175741A2 (OSRAM)
ZA (1) ZA201309295B (OSRAM)

Families Citing this family (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3434769B1 (en) 2009-10-30 2020-11-25 Novartis AG Universal fibronectin type iii bottom-side binding domain libraries
EP3345926B1 (en) 2010-05-06 2023-04-05 Novartis AG Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (lrp6) antibodies
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
EP2621953B1 (en) 2010-09-30 2017-04-05 Ablynx N.V. Biological materials related to c-met
EP3363813A1 (en) 2011-06-23 2018-08-22 Ablynx NV Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobin single variable domains
PL2723771T3 (pl) 2011-06-23 2020-04-30 Ablynx Nv Białka wiążące albuminy surowicy
ES2622006T5 (es) 2011-06-23 2022-10-13 Ablynx Nv Técnicas para predecir, detectar y reducir la interferencia proteica no específica en ensayos que implican dominios variables individuales de inmunoglobulina
SG10201605891TA (en) * 2011-08-17 2016-09-29 Glaxo Group Ltd Modified proteins and peptides
WO2013073968A2 (en) * 2011-09-12 2013-05-23 Industrial Research Limited Agents for modulation of cell signalling
US9346884B2 (en) 2011-09-30 2016-05-24 Ablynx N.V. Biological materials related to c-Met
TW201323442A (zh) 2011-11-04 2013-06-16 Novartis Ag 低密度脂蛋白相關蛋白６（ｌｒｐ６）－半衰期延長構築體
US9458450B2 (en) 2012-03-15 2016-10-04 Flodesign Sonics, Inc. Acoustophoretic separation technology using multi-dimensional standing waves
US10967298B2 (en) 2012-03-15 2021-04-06 Flodesign Sonics, Inc. Driver and control for variable impedence load
US9950282B2 (en) 2012-03-15 2018-04-24 Flodesign Sonics, Inc. Electronic configuration and control for acoustic standing wave generation
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
US20140161796A1 (en) * 2012-09-13 2014-06-12 Andreas Loew Single chain proteins with c-terminal modifications
US9725710B2 (en) 2014-01-08 2017-08-08 Flodesign Sonics, Inc. Acoustophoresis device with dual acoustophoretic chamber
EP3143042B1 (en) 2014-05-16 2020-06-10 Ablynx N.V. Immunoglobulin variable domains
US11009511B2 (en) * 2014-05-16 2021-05-18 Ablynx N.V. Methods for detecting and/or measuring anti-drug antibodies, in particular treatment-emergent anti-drug antibodies
NL2013661B1 (en) 2014-10-21 2016-10-05 Ablynx Nv KV1.3 Binding immunoglobulins.
CA2974192C (en) 2015-01-21 2024-02-20 Inhibrx Biopharma LLC Non-immunogenic single domain antibodies
CA2981098A1 (en) 2015-03-31 2016-10-06 Vhsquared Limited Peptide construct having a protease-cleavable linker
AU2016239951A1 (en) 2015-03-31 2017-09-07 Sorriso Pharmaceuticals, Inc. Polypeptides
ES2973042T3 (es) 2015-03-31 2024-06-18 Sorriso Pharmaceuticals Inc Polipéptidos
AU2016239844B2 (en) 2015-04-02 2021-05-13 Ablynx N.V. Bispecific CXCR4-CD-4 polypeptides with potent anti-HIV activity
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11021699B2 (en) 2015-04-29 2021-06-01 FioDesign Sonics, Inc. Separation using angled acoustic waves
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
CA3155409A1 (en) 2015-05-13 2016-11-17 Ablynx N.V. T cell recruiting polypeptides based on cd3 reactivity
AU2016259792B2 (en) 2015-05-13 2019-07-25 Ablynx N.V. T cell recruiting polypeptides based on TCR alpha/beta reactivity
US11474085B2 (en) 2015-07-28 2022-10-18 Flodesign Sonics, Inc. Expanded bed affinity selection
US11459540B2 (en) 2015-07-28 2022-10-04 Flodesign Sonics, Inc. Expanded bed affinity selection
CN108350069B (zh) * 2015-10-30 2021-11-12 埃博灵克斯股份有限公司 针对il-23的多肽
TWI746473B (zh) * 2015-11-02 2021-11-21 美商辛分子醫藥有限公司 針對細胞內抗原之單域抗體
NO2768984T3 (OSRAM) 2015-11-12 2018-06-09
CA3005082A1 (en) * 2015-11-12 2017-05-18 Ablynx Nv Improved p2x7 receptor binders and polypeptides comprising the same
AU2016351710B2 (en) 2015-11-13 2023-08-03 Ablynx Nv Improved serum albumin-binding immunoglobulin variable domains
WO2017085172A2 (en) * 2015-11-18 2017-05-26 Ablynx Nv Improved serum albumin binders
JP6779997B2 (ja) 2015-11-18 2020-11-04 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｐｄ１／ｃｔｌａ４結合性物質
BR112018010084A2 (pt) 2015-11-18 2018-11-13 Merck Sharp & Dohme ligantes de pd1 e/ou lag3
CN108473565B (zh) 2015-11-18 2022-05-27 默沙东公司 Ctla4结合剂
MA43302A (fr) 2015-11-27 2021-03-17 Ablynx Nv Polypeptides inhibant le ligand cd40l
RS60823B1 (sr) 2015-12-04 2020-10-30 Boehringer Ingelheim Int Biparatopski polipeptidi koji antagonizuju wnt signalizaciju u tumorskim ćelijama
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
US11085035B2 (en) 2016-05-03 2021-08-10 Flodesign Sonics, Inc. Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
IL263704B2 (en) * 2016-06-23 2024-09-01 Ablynx Nv Improved pharmacokinetic assays for immunoglobulin single variable domains
WO2018050833A1 (en) 2016-09-15 2018-03-22 Ablynx Nv Immunoglobulin single variable domains directed against macrophage migration inhibitory factor
EP3519438A1 (en) 2016-09-30 2019-08-07 VHsquared Limited Compositions
CN110494543A (zh) 2016-10-19 2019-11-22 弗洛设计声能学公司 通过声学的亲和细胞提取
MX2019005696A (es) 2016-11-16 2019-08-14 Ablynx Nv Polipeptidos de reclutamiento de celulas t capaces de unir cd123 y tcr alfa/beta.
EP3551656A1 (en) 2016-12-07 2019-10-16 Ablynx NV Improved serum albumin binding immunoglobulin single variable domains
US11897944B2 (en) 2017-01-17 2024-02-13 Ablynx N.V. Immunoglobulin single variable domain (ISVD) capable of binding to serum albumin
SG11201906264YA (en) 2017-01-17 2019-08-27 Ablynx Nv Improved serum albumin binders
CA3056727A1 (en) 2017-03-31 2018-10-04 Ablynx N.V. Improved immunogenicity assays
AU2018276409B2 (en) 2017-05-31 2025-02-27 Ablynx N.V. Polypeptides antagonizing Wnt signaling in tumor cells
TWI825021B (zh) 2017-06-02 2023-12-11 德商麥克專利有限公司 與ｍｍｐ１３結合之免疫球蛋白
CN111032695B (zh) 2017-06-02 2024-06-25 默克专利股份有限公司 结合adamts的免疫球蛋白
TW202428621A (zh) 2017-06-02 2024-07-16 德商麥克專利有限公司 與ａｄａｍｔｓ５、ｍｍｐ１３及聚集蛋白聚醣結合的多肽
TW202413408A (zh) 2017-06-02 2024-04-01 比利時商艾伯林克斯公司 結合聚集蛋白聚糖之免疫球蛋白
WO2019016237A1 (en) 2017-07-19 2019-01-24 Vib Vzw AGENTS FOR CONNECTING TO SERUM ALBUMIN
EP3674191B1 (en) 2017-08-23 2021-07-14 Honda Motor Co., Ltd. Air bag device for saddle-type vehicles
CA3076791A1 (en) 2017-10-31 2019-05-09 Vib Vzw Novel antigen-binding chimeric proteins and methods and uses thereof
WO2019118921A1 (en) 2017-12-14 2019-06-20 Flodesign Sonics, Inc. Acoustic transducer drive and controller
EP3569618A1 (en) 2018-05-19 2019-11-20 Boehringer Ingelheim International GmbH Antagonizing cd73 antibody
TWI848953B (zh) 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
CA3098206A1 (en) 2018-07-10 2020-01-16 Regeneron Pharmaceuticals, Inc. Methods for mitigating drug target interference in an anti-drug antibody (ada) immunoassay
FR3088640A1 (fr) 2018-10-14 2020-05-22 Smart Diagnostix Pharma Nouveau polypeptide se liant specifiquement a la proteine p16
US20220289837A1 (en) 2019-04-30 2022-09-15 Vib Vzw Cystic Fibrosis Transmembrane Conductance Regulator Stabilizing Agents
JP7692844B2 (ja) 2019-06-21 2025-06-16 ソリッソ ファーマシューティカルズ，インク． ポリペプチド
AU2020296979A1 (en) 2019-06-21 2022-02-24 Sorriso Pharmaceuticals, Inc. Polypeptides
TWI878355B (zh) 2019-10-02 2025-04-01 德商百靈佳殷格翰國際股份有限公司 用於癌症治療之多重專一性結合蛋白
GB201914468D0 (en) 2019-10-07 2019-11-20 Crescendo Biologics Ltd Binding Molecules
WO2021105438A1 (en) 2019-11-27 2021-06-03 Vib Vzw Positive allosteric modulators of the calcium-sensing receptor
JP7719775B2 (ja) 2019-12-06 2025-08-06 アブリンクス エン．ヴェー． ＴＮＦαおよびＯＸ４０Ｌを標的とする免疫グロブリン単一可変ドメインを含むポリペプチド
CA3163877A1 (en) 2019-12-06 2021-06-10 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting tnf.alpha. and il-23
AR120698A1 (es) 2019-12-09 2022-03-09 Ablynx Nv Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y tslp
AU2020400938A1 (en) 2019-12-09 2022-07-28 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting IL-13 and TSLP
WO2021123360A1 (en) 2019-12-20 2021-06-24 Vib Vzw Nanobody exchange chromatography
WO2021156490A2 (en) 2020-02-06 2021-08-12 Vib Vzw Corona virus binders
US20230087785A1 (en) 2020-02-25 2023-03-23 Vib Vzw Leucine-Rich Repeat Kinase 2 Allosteric Modulators
WO2022003156A1 (en) 2020-07-02 2022-01-06 Oncurious Nv Ccr8 non-blocking binders
JP2023544124A (ja) 2020-09-25 2023-10-20 アブリンクス エン．ヴェー． Ｉｌ－１３およびｏｘ４０ｌを標的化する免疫グロブリン単一可変ドメインを含むポリペプチド
WO2022117572A2 (en) 2020-12-02 2022-06-09 Oncurious Nv An ltbr agonist in combination therapy against cancer
WO2022117569A1 (en) 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
PH12023500013A1 (en) 2020-12-04 2024-03-11 Tidal Therapeutics Inc Ionizable cationic lipids and lipi nanoparticles, and methods of synthesis and use thereof
BR112023011782A2 (pt) 2020-12-14 2023-10-31 Takeda Pharmaceuticals Co Proteínas de ligação condicionalmente biespecíficas
JP2023553694A (ja) 2020-12-18 2023-12-25 アブリンクス エン．ヴェー． ＩＬ－６およびＴＮＦ－αを標的化する免疫グロブリン単一可変ドメインを含むポリペプチド
US20240092919A1 (en) 2020-12-18 2024-03-21 Ablynx N. V. T cell recruiting polypeptides based on tcr alpha/beta reactivity
MX2023007308A (es) 2020-12-18 2023-07-04 Ablynx Nv Polipeptidos que comprenden dominios variables simples de inmunoglobulina dirigidos a glypican-3 y al receptor de celulas t.
GB202020502D0 (en) 2020-12-23 2021-02-03 Vib Vzw Antibody composistion for treatment of corona virus infection
JP2024506020A (ja) 2021-02-05 2024-02-08 ブイアイビー ブイゼットダブリュ サルベコウイルス結合剤
CN117794566A (zh) 2021-02-05 2024-03-29 Vib研究所 沙贝病毒结合剂
US20250263490A1 (en) 2021-02-19 2025-08-21 Vib Vzw Cation-Independent Mannose-6-Phosphate Receptor Binders
CN113173978B (zh) * 2021-04-22 2024-03-01 温州医科大学 一种对hpv16e6蛋白具有结合亲和力的多肽及其应用
WO2023016828A2 (en) 2021-07-30 2023-02-16 Vib Vzw Cation-independent mannose-6-phosphate receptor binders for targeted protein degradation
EP4435002A4 (en) 2021-11-29 2025-03-26 Jiangsu Hengrui Pharmaceuticals Co., Ltd. MODIFIED PROTEIN OR POLYPEPTIDE
EP4448783A1 (en) 2021-12-13 2024-10-23 Heraeus Medical GmbH Tests and methods for detecting bacterial infection
TW202342508A (zh) 2021-12-17 2023-11-01 比利時商艾伯霖克斯公司 包含靶向ＴＣＲαβ、ＣＤ３３和ＣＤ１２３的免疫球蛋白單可變結構域的多肽
US20250304664A1 (en) 2022-01-12 2025-10-02 Vib Vzw Human NTCP Binders For Therapeutic Use And Liver-Specific Targeted Delivery
TW202342521A (zh) 2022-02-23 2023-11-01 日商武田藥品工業股份有限公司 條件性雙特異性結合蛋白
EP4508082A1 (en) 2022-04-13 2025-02-19 Vib Vzw An ltbr agonist in combination therapy against cancer
EP4526340A1 (en) 2022-05-18 2025-03-26 Vib Vzw Sarbecovirus spike s2 subunit binders
CN119630637A (zh) 2022-06-08 2025-03-14 潮汐疗法公司 可电离阳离子脂质和脂质纳米颗粒及其合成和使用方法
JP2025530888A (ja) 2022-06-14 2025-09-18 アブリンクス エン．ヴェー． Ｔ細胞レセプターを標的とするイムノグロブリン単一可変ドメイン
JP2025526384A (ja) 2022-07-27 2025-08-13 アブリンクス エン．ヴェー． 新生児型Ｆｃ受容体の特異的エピトープに結合するポリペプチド
WO2024068744A1 (en) 2022-09-27 2024-04-04 Vib Vzw Antivirals against human parainfluenza virus
WO2024083843A1 (en) 2022-10-18 2024-04-25 Confo Therapeutics N.V. Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders
EP4357778A1 (en) 2022-10-20 2024-04-24 Heraeus Medical GmbH Treatment of microbial infections diagnosed using the biomarker d-lactate
KR20250124145A (ko) 2022-12-21 2025-08-19 젠자임 코포레이션 항-pd-1×4-1bb 결합 단백질
US20240415974A1 (en) 2022-12-23 2024-12-19 Ablynx N.V. Protein-based conjugation carriers
AU2024207151A1 (en) 2023-01-09 2025-06-19 Odyssey Therapeutics, Inc. Anti-tnfr2 antigen-binding proteins and uses thereof
AU2024218347A1 (en) 2023-02-10 2025-08-28 Amunix Pharmaceuticals, Inc. Compositions targeting prostate-specific membrane antigen (psma) and methods for making and using the same
TW202448926A (zh) 2023-02-17 2024-12-16 比利時商艾伯霖克斯公司 結合新生兒fc受體之多肽
WO2024175787A1 (en) 2023-02-24 2024-08-29 Vrije Universiteit Brussel Anti-inflammatory pannexin 1 channel inhibitors
AR132121A1 (es) 2023-03-14 2025-05-28 Odyssey Therapeutics Inc Proteínas de unión a antígeno anti-cd25 y usos de las mismas
WO2024208816A1 (en) 2023-04-03 2024-10-10 Vib Vzw Blood-brain barrier crossing antibodies
WO2024231447A1 (en) 2023-05-08 2024-11-14 Sanofi Glycosylation of immunoglobulin single variable domains
AU2024273077A1 (en) 2023-05-17 2025-11-13 Odyssey Therapeutics, Inc. Modified single-domain antibodies
WO2024261235A1 (en) 2023-06-22 2024-12-26 Ablynx Nv Chimeric proteins for modulating cytokine receptor activity
WO2025006846A2 (en) 2023-06-29 2025-01-02 Odyssey Therapeutics, Inc. Anti-trailr2 antigen-binding proteins and uses thereof
WO2025008537A1 (en) 2023-07-05 2025-01-09 Ablynx Nv Improved fcrn antagonists for treatment of igg-related diseases and disorders
AR133725A1 (es) 2023-09-04 2025-10-29 Sanofi Sa Polipéptidos para uso en el tratamiento de tumores que expresan glipicano-3
US20250129145A1 (en) 2023-09-22 2025-04-24 Ablynx N.V. Bi- and multivalent albumin binders
WO2025080751A2 (en) 2023-10-13 2025-04-17 Odyssey Therapeutics, Inc. Anti-cdh17 antigen-binding proteins and uses thereof
WO2025099632A1 (en) 2023-11-08 2025-05-15 Sanofi Cd25 based lysosomal degrader and uses thereof
WO2025109176A1 (en) 2023-11-22 2025-05-30 Exevir Bio Bv Optimized sarbecovirus spike s2 subunit binders and compositions comprising the same
WO2025114529A1 (en) 2023-12-01 2025-06-05 Ablynx Nv Multispecific antibodies recognising human serum albumin, tcr and a tumor antigen recognising moiety
WO2025125577A1 (en) 2023-12-14 2025-06-19 Vib Vzw Antibodies against influenza b virus
WO2025133166A1 (en) 2023-12-22 2025-06-26 Ablynx Nv Protein-based carriers for site-specific amine conjugation
WO2025133253A2 (en) 2023-12-22 2025-06-26 Ablynx Nv Protein-based conjugation carriers for intranuclear delivery
WO2025174825A2 (en) 2024-02-12 2025-08-21 Aera Therapeutics, Inc. Delivery compositions
WO2025181155A1 (en) 2024-02-26 2025-09-04 Vib Vzw Human beta-glucocerebrosidase binders and uses thereof
WO2025217240A1 (en) 2024-04-10 2025-10-16 Odyssey Therapeutics, Inc. Anti-tnfr2 antigen-binding proteins and uses thereof
WO2025219231A1 (en) 2024-04-15 2025-10-23 Vib Vzw Computer-implemented means and methods for the de novo design of antibodies targeting a specific epitope

Family Cites Families (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1545106C3 (de) 1963-07-16 1979-05-31 Union Carbide Corp., New York, N.Y. (V.St.A.) Verfahren zur Herstellung von linearen Polyarylenpolyäthern
FI903489A0 (fi) 1988-11-11 1990-07-10 Medical Res Council Ligander med en enda sektion, receptorer innehaollande naemnda ligander, foerfaranden foer deras framstaellning samt anvaendning av liganderna och receptorerna.
CA2016842A1 (en) 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
US6150584A (en) * 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
GB9016299D0 (en) * 1990-07-25 1990-09-12 Brien Caroline J O Binding substances
EP0542810A1 (en) 1990-08-02 1993-05-26 B.R. Centre Limited Methods for the production of proteins with a desired function
US5608039A (en) * 1990-10-12 1997-03-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Single chain B3 antibody fusion proteins and their uses
EP0488470B1 (en) 1990-11-26 1997-05-28 Akzo Nobel N.V. Method for the production of antibodies
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
EP2309275A1 (en) 1999-07-05 2011-04-13 K.U.Leuven Research & Development Detection of Von-Willebrand factor (vwf) activity
US6541225B1 (en) 2000-01-26 2003-04-01 Raven Biotechnologies, Inc. Methods and compositions for generating human monoclonal antibodies
WO2002026829A1 (en) 2000-09-25 2002-04-04 Rega Stichting Vzw Method for the production of human antibodies, antibodies thus obtained and their use in therapy and diagnosis
DK1360207T3 (da) 2000-12-13 2011-09-05 Bac Ip B V Proteinarray af variable domæner af tunge immunoglobulinkæder fra kameler
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
FR2846667B1 (fr) 2002-11-06 2004-12-31 Pasteur Institut Fragments variables d'anticorps de camelides a chaine unique diriges contre le peptide beta-amyloide 1-42 et leurs applications pour le diagnostic et le traitement des maladies neuroagregatives
CA2505326A1 (en) 2002-11-08 2004-05-21 Ablynx N.V. Camelidae antibodies against immunoglobulin e and use thereof for the treatment of allergic disorders
CA2507004A1 (en) 2002-12-03 2004-06-17 Celltech R & D Limited Assay for identifying antibody producing cells
JP2006523090A (ja) * 2002-12-27 2006-10-12 ドマンティス リミテッド リガンドに、そしてリガンド受容体に特異的な二重特異性単一ドメイン抗体
NZ540771A (en) 2003-01-10 2009-05-31 Ablynx Nv Recombinant VHH single domain antibody from camelidae against von willebrand factor (vWF) or against collagen
EP1585767A2 (en) * 2003-01-16 2005-10-19 Genentech, Inc. Synthetic antibody phage libraries
US20070087331A1 (en) 2003-05-15 2007-04-19 Cytos Biotechnology Ag Selection of b cells with specificity if interest: method of preparation and use
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
KR20070117002A (ko) 2003-11-04 2007-12-11 도꾸리쯔교세이호징 가가꾸 기쥬쯔 신꼬 기꼬 고지혈증·고알부민혈증 모델 동물
US7476724B2 (en) 2004-08-05 2009-01-13 Genentech, Inc. Humanized anti-cmet antibodies
CN101133084A (zh) 2004-12-02 2008-02-27 多曼蒂斯有限公司 采用白细胞介素-1ⅰ型受体拮抗剂治疗呼吸道疾病的方法
JP2008528010A (ja) 2005-01-31 2008-07-31 アブリンクス ナームローゼ フェンノートシャップ 重鎖抗体の可変ドメイン配列を作出する方法
HUE045710T2 (hu) 2005-05-18 2020-01-28 Ablynx Nv Javított, alfa tumor nekrózis faktor elleni nanobodies
US7807162B2 (en) 2005-05-20 2010-10-05 Ablynx N.V. Single domain VHH antibodies against von Willebrand factor
DE102005023617A1 (de) 2005-05-21 2006-11-23 Aspre Ag Verfahren zum Mischen von Farben in einem Display
US7875465B2 (en) 2005-05-31 2011-01-25 Canon Kabushiki Kaisha Target substance capturing molecule
JP2007008925A (ja) * 2005-05-31 2007-01-18 Canon Inc 標的物質捕捉分子
US7989219B2 (en) * 2005-05-31 2011-08-02 Canon Kabushiki Kaisha Bispecific capturing molecule
TW200730539A (en) 2005-12-01 2007-08-16 Domantis Ltd Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1
TW200736276A (en) 2005-12-01 2007-10-01 Domantis Ltd Competitive domain antibody formats that bind interleukin 1 receptor type 1
FR2894741B1 (fr) 2005-12-08 2009-12-04 Centre Nat Etd Spatiales Chaine de reception par satellite
US20100047171A1 (en) * 2006-01-24 2010-02-25 Roland Beckmann Fusion Proteins That Contain Natural Junctions
WO2007126799A2 (en) 2006-03-30 2007-11-08 Novartis Ag Compositions and methods of use for antibodies of c-met
US7741273B2 (en) 2006-04-13 2010-06-22 Warsaw Orthopedic, Inc. Drug depot implant designs
CN103524619B (zh) 2006-08-03 2016-10-05 阿斯利康(瑞典)有限公司 针对αVβ6的抗体及其应用
CA2666599A1 (en) 2006-08-18 2008-02-21 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
US20100113339A1 (en) 2006-09-08 2010-05-06 Ablynx N. V. Serum albumin binding proteins with long half-lives
AU2007306340A1 (en) * 2006-10-11 2008-04-17 Ablynx N.V. Amino acid sequences that bind to serum proteins in a manner that is essentially independent of the pH, compounds comprising the same, and use thereof
AU2007328900A1 (en) * 2006-12-05 2008-06-12 Ablynx N.V. Peptides capable of binding to serum proteins
EP2121751B1 (en) 2006-12-08 2017-01-25 Lexicon Pharmaceuticals, Inc. Monoclonal antibodies against angptl3
CA2672595A1 (en) 2006-12-15 2008-06-19 Guy Hermans Amino acid sequences that modulate the interaction between cells of the immune system
EP2097451A2 (en) * 2006-12-22 2009-09-09 Ablynx N.V. Anti-chemokine (ccl2, ccl3, ccl5, cxcl11, cxcl12) single-domain antibodies
CA2678218A1 (en) 2007-02-21 2008-08-28 Ablynx N.V. Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization
GB0706793D0 (en) 2007-04-05 2007-05-16 Evotec Ag Compounds
US8623361B2 (en) * 2007-05-24 2014-01-07 Ablynx N.V. Amino acid sequences directed against RANK-L and polypeptides comprising the same for the treatment of bone diseases and disorders
EP2014681A1 (en) 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
AR062123A1 (es) * 2007-07-27 2008-10-15 Inst Nac De Tecnologia Agropec Dominio vhh monomerico derivado de anticuerpos de camelidos anti-vp6 dominio dimerico, metodo de inmunodeteccion de rotavirus, composiciones, metodos de prevencion y tratamiento de infecciones con rotavirus
JP6126773B2 (ja) * 2007-09-04 2017-05-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 癌のターゲッティングおよび検出のための高親和性抗前立腺幹細胞抗原（ｐｓｃａ）抗体
BRPI0817257A2 (pt) 2007-09-24 2015-06-16 Univ Vanderbilt Anticorpos moniclonais para vírus sincital respiratório e usos dos mesmos
AU2008328781A1 (en) 2007-11-27 2009-06-04 Ablynx N.V. Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
CA2709399C (en) * 2007-12-28 2021-01-19 Genentech, Inc. Anti-hedgehog antibodies
EP2250201B1 (en) 2008-01-29 2014-04-30 Ludwig Institute for Cancer Research Ltd. Membrane transporter napi2b (slc34a2) epitope for antibody therapy, antibodies directed thereto, and target for cancer therapy
JP2011516603A (ja) 2008-04-17 2011-05-26 アブリンクス エン．ヴェー． 血清タンパク質と結合することが可能なペプチド、並びにこれを含む化合物、構築物及びポリペプチド
DE102008023620A1 (de) 2008-05-15 2009-11-19 Mettler-Toledo (Albstadt) Gmbh Funktionseinheit mit einer aufrufbaren Funktion und Verfahren zu deren Aufruf
BRPI0911984A2 (pt) 2008-05-16 2016-09-20 Ablynx Nv sequências de aminoácidos direncionadas contra cxcr4 e outros compostos gpcrs compreendendo os mesmos
US7858729B2 (en) 2008-05-29 2010-12-28 Novomer, Inc. Methods of controlling molecular weight distribution of polymers and compositions thereof
AU2009254501B2 (en) 2008-06-05 2014-07-31 Ablynx N.V. Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
EP2143735A1 (en) 2008-07-10 2010-01-13 Institut Pasteur Variable domains of camelid heavy-chain antibodies directed against glial fibrillary acidic proteins
US20110200525A1 (en) * 2008-10-09 2011-08-18 Patz Jr Edward F Vhh antibody fragments for use in the detection and treatment of cancer
US8372808B2 (en) 2008-10-31 2013-02-12 Wisconsin Alumni Research Foundation Suppression of glial fibrillary acidic protein
US10005830B2 (en) † 2009-03-05 2018-06-26 Ablynx N.V. Antigen binding dimer-complexes, methods of making/avoiding and uses thereof
WO2010108937A2 (en) 2009-03-27 2010-09-30 Glaxo Group Limited Drug fusions and conjugates
SG174862A1 (en) 2009-04-10 2011-11-28 Ablynx Nv Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorder
US8450888B2 (en) 2009-04-20 2013-05-28 General Electric Company Integrated brushless starter/generator system
WO2010130832A2 (en) 2009-05-15 2010-11-18 Ablynx N.V. Amino acid sequences directed against dickkopf-1 and polypeptides comprising the same for the treatment of diseases and disorders associated with bone loss and/or osteolytic lesions
US9150640B2 (en) 2009-07-10 2015-10-06 Ablynx N.V. Method for the production of variable domains
US8306355B2 (en) 2009-07-13 2012-11-06 Sharp Laboratories Of America, Inc. Methods and systems for reducing compression artifacts
US9644022B2 (en) * 2009-11-30 2017-05-09 Ablynx N.V. Amino acid sequences directed against human respiratory syncytial virus (HRSV) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
EP2513145B1 (en) 2009-12-14 2018-01-24 Ablynx N.V. Single variable domain antibodies against ox40l, constructs and therapeutic use
MX2012007153A (es) 2009-12-18 2012-07-03 Sanofi Sa Nuevos anticuerpos antagonistas y sus fragmentos fab contra gpvi y sus usos.
KR101758703B1 (ko) 2009-12-23 2017-07-18 에스바테크 - 어 노바티스 컴파니 엘엘씨 면역원성의 감소 방법
UY33253A (es) 2010-03-03 2011-09-30 Boehringer Ingelheim Int Polipéptidos de unión a a-beta
CN103003307B (zh) 2010-03-10 2017-08-11 根马布股份公司 抗c‑MEt的单克隆抗体
US8937164B2 (en) * 2010-03-26 2015-01-20 Ablynx N.V. Biological materials related to CXCR7
AU2011247612A1 (en) 2010-04-30 2012-12-06 Ablynx Nv Amino acid sequences of nanobodies directed against p19 subunit of the heterodimeric cytokine IL-23
CN102906118B (zh) 2010-05-20 2017-07-28 埃博灵克斯股份有限公司 与her3相关的生物材料
EP2621953B1 (en) 2010-09-30 2017-04-05 Ablynx N.V. Biological materials related to c-met
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
KR101886898B1 (ko) * 2011-01-06 2018-08-08 글락소 그룹 리미티드 Ｔｇｆ-베타 수용체 ｉｉ에 결합하는 리간드
CN106039306A (zh) 2011-03-30 2016-10-26 埃博灵克斯股份有限公司 使用针对TNFα的单结构域抗体治疗免疫病症的方法
WO2012130314A1 (en) † 2011-03-31 2012-10-04 Elara Pharmaceuticals Gmbh Composition comprising docetaxel
PL2723771T3 (pl) 2011-06-23 2020-04-30 Ablynx Nv Białka wiążące albuminy surowicy
ES2622006T5 (es) 2011-06-23 2022-10-13 Ablynx Nv Técnicas para predecir, detectar y reducir la interferencia proteica no específica en ensayos que implican dominios variables individuales de inmunoglobulina
US20150344568A1 (en) 2011-06-23 2015-12-03 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
HK1198446A1 (en) 2011-07-27 2015-04-24 Glaxo Group Limited Anti-vegf single variable domains fused to fc domains
SG10201605891TA (en) * 2011-08-17 2016-09-29 Glaxo Group Ltd Modified proteins and peptides
US9346884B2 (en) 2011-09-30 2016-05-24 Ablynx N.V. Biological materials related to c-Met
US8614548B2 (en) 2012-01-19 2013-12-24 Sonoco Development Incorporated Electroluminescent display and method for production
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
CN105643698A (zh) 2012-05-22 2016-06-08 欧文斯科宁知识产权资产有限公司 层压泡沫产品和制造层压泡沫产品的方法
WO2014111550A1 (en) † 2013-01-17 2014-07-24 Glaxosmithkline Intellectual Property Development Limited Modified anti-serum albumin binding proteins
US11009511B2 (en) 2014-05-16 2021-05-18 Ablynx N.V. Methods for detecting and/or measuring anti-drug antibodies, in particular treatment-emergent anti-drug antibodies
EP3143042B1 (en) 2014-05-16 2020-06-10 Ablynx N.V. Immunoglobulin variable domains
CA2963712A1 (en) 2014-10-21 2016-04-28 Ablynx Nv Treatment of il-6r related diseases
NO2768984T3 (OSRAM) 2015-11-12 2018-06-09
AU2016351710B2 (en) 2015-11-13 2023-08-03 Ablynx Nv Improved serum albumin-binding immunoglobulin variable domains
JP6779997B2 (ja) 2015-11-18 2020-11-04 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｐｄ１／ｃｔｌａ４結合性物質
CN108473565B (zh) 2015-11-18 2022-05-27 默沙东公司 Ctla4结合剂
BR112018010084A2 (pt) 2015-11-18 2018-11-13 Merck Sharp & Dohme ligantes de pd1 e/ou lag3
WO2017085172A2 (en) 2015-11-18 2017-05-26 Ablynx Nv Improved serum albumin binders
WO2017129630A1 (en) 2016-01-26 2017-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-vwf d'd3 single-domain antibodies and polypeptides comprising thereof
EP3551656A1 (en) * 2016-12-07 2019-10-16 Ablynx NV Improved serum albumin binding immunoglobulin single variable domains
SG11201906264YA (en) * 2017-01-17 2019-08-27 Ablynx Nv Improved serum albumin binders
CN111032695B (zh) * 2017-06-02 2024-06-25 默克专利股份有限公司 结合adamts的免疫球蛋白
TW202413408A (zh) 2017-06-02 2024-04-01 比利時商艾伯林克斯公司 結合聚集蛋白聚糖之免疫球蛋白
TWI825021B (zh) * 2017-06-02 2023-12-11 德商麥克專利有限公司 與ｍｍｐ１３結合之免疫球蛋白
TW202428621A (zh) * 2017-06-02 2024-07-16 德商麥克專利有限公司 與ａｄａｍｔｓ５、ｍｍｐ１３及聚集蛋白聚醣結合的多肽
EP3749696A1 (en) * 2018-02-06 2020-12-16 Ablynx N.V. Methods of treating initial episode of ttp with immunoglobulin single variable domains
AR120698A1 (es) 2019-12-09 2022-03-09 Ablynx Nv Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y tslp
MX2023007308A (es) * 2020-12-18 2023-07-04 Ablynx Nv Polipeptidos que comprenden dominios variables simples de inmunoglobulina dirigidos a glypican-3 y al receptor de celulas t.

Also Published As

Publication number Publication date
CN104203975B (zh) 2018-05-11
AU2020230299B2 (en) 2022-10-06
US20180009888A9 (en) 2018-01-11
AU2024200309A1 (en) 2024-02-08
MX2013014614A (es) 2014-08-01
DK2723769T4 (da) 2022-09-05
CN108659120A (zh) 2018-10-16
CN108653728A (zh) 2018-10-16
US20200325221A1 (en) 2020-10-15
PH12013502669B1 (en) 2018-08-10
IL229503B (en) 2022-06-01
CA2837998C (en) 2022-03-01
KR20220114104A (ko) 2022-08-17
WO2012175741A2 (en) 2012-12-27
AU2018202782B2 (en) 2020-07-16
KR20210047369A (ko) 2021-04-29
AU2012273929B2 (en) 2017-04-27
US11192938B2 (en) 2021-12-07
AU2018202782A1 (en) 2018-05-10
JP2022031790A (ja) 2022-02-22
KR20240033183A (ko) 2024-03-12
RU2019128430A (ru) 2019-10-25
KR20190041513A (ko) 2019-04-22
NZ780183A (en) 2024-12-20
PH12017501178A1 (en) 2018-07-23
AU2019201606A1 (en) 2019-04-04
SG10201707604SA (en) 2017-11-29
PH12022550312A1 (en) 2023-01-23
US20210403536A1 (en) 2021-12-30
US20210388061A1 (en) 2021-12-16
KR102880093B1 (ko) 2025-10-31
NZ716279A (en) 2017-07-28
US20210388062A1 (en) 2021-12-16
IL293163A (en) 2022-07-01
KR20180086280A (ko) 2018-07-30
PL2723769T3 (pl) 2017-07-31
AU2019201606B2 (en) 2021-04-01
CN108659121A (zh) 2018-10-16
BR122018012485B1 (pt) 2022-09-20
IL250396A0 (en) 2017-03-30
SG10201805064SA (en) 2018-07-30
KR102430693B1 (ko) 2022-08-08
BR112013032145A8 (pt) 2018-07-03
KR102240318B1 (ko) 2021-04-15
KR101965462B1 (ko) 2019-04-04
JP2017160230A (ja) 2017-09-14
IL293155A (en) 2022-07-01
AU2017204339A1 (en) 2017-07-13
CA3141978A1 (en) 2012-12-27
PH12022550313A1 (en) 2023-01-23
KR20190107200A (ko) 2019-09-18
KR102025035B1 (ko) 2019-11-04
LT2723769T (lt) 2017-04-10
SG194982A1 (en) 2013-12-30
CN108653728B (zh) 2022-11-18
PH12022550309A1 (en) 2023-01-23
ES2622006T3 (es) 2017-07-05
AU2017204339B2 (en) 2019-03-28
AU2021201506B2 (en) 2023-10-19
US20140199295A1 (en) 2014-07-17
US20200216532A1 (en) 2020-07-09
US20220119497A1 (en) 2022-04-21
CN108663504A (zh) 2018-10-16
RU2700630C2 (ru) 2019-09-18
BR112013032145A2 (pt) 2017-12-05
JP2024050769A (ja) 2024-04-10
JP2021107426A (ja) 2021-07-29
JP2018162305A (ja) 2018-10-18
JP6982400B2 (ja) 2021-12-17
ES2622006T5 (es) 2022-10-13
PH12022550310A1 (en) 2023-01-23
HUE031828T2 (en) 2017-08-28
KR102246924B1 (ko) 2021-04-30
JP6258199B2 (ja) 2018-01-10
PH12013502669A1 (en) 2014-02-10
CA2837998A1 (en) 2012-12-27
CN104203975A (zh) 2014-12-10
AU2021201506A1 (en) 2021-03-25
EP2723769B1 (en) 2017-01-11
JP2014520134A (ja) 2014-08-21
CN108663504B (zh) 2021-06-22
US20180355031A1 (en) 2018-12-13
IL250396B (en) 2022-06-01
US12006352B2 (en) 2024-06-11
CA3142288A1 (en) 2012-12-27
PH12022550311A1 (en) 2023-01-23
US10858418B2 (en) 2020-12-08
MX350074B (es) 2017-08-25
AU2020230299A1 (en) 2020-10-01
BR122017005075B1 (pt) 2022-09-20
KR20140040779A (ko) 2014-04-03
BR122017005075A2 (pt) 2019-09-03
US20170275360A1 (en) 2017-09-28
JP6869923B2 (ja) 2021-05-12
WO2012175741A3 (en) 2013-02-14
US11192937B2 (en) 2021-12-07
IN2014CN00373A (OSRAM) 2015-04-03
PL2723769T5 (pl) 2022-10-17
US20220298227A9 (en) 2022-09-22
DK2723769T3 (en) 2017-04-03
MX2018007826A (es) 2021-12-08
EP2723769A2 (en) 2014-04-30
NZ617995A (en) 2016-06-24
IL229503A0 (en) 2014-01-30
SG10201605048XA (en) 2016-07-28
RU2014102007A (ru) 2015-11-27
US20170275361A1 (en) 2017-09-28
US20230242620A1 (en) 2023-08-03
EP2723769B2 (en) 2022-06-15
PT2723769T (pt) 2017-04-04
BR112013032145B1 (pt) 2022-09-20

Similar Documents

Publication Publication Date Title
IL250396A0 (en) Techniques for predicting, detecting, and reducing A-specific protein interference in assays involving single immunoglobulin variable domains
RS55775B1 (sr) Tehnike za predviđanje, otkrivanje i smanjenje nespecifične proteinske interferencije u testovima koji uključuju pojedinačne varijabilne domene imunoglobulina
HUE037095T2 (hu) Eljárások és reagensek monoklonális ellenanyagok elõállítására
ZA201400768B (en) Interleukin-31 monoclonal antibody
GB201115529D0 (en) Antibodies, uses and methods
PL2673641T3 (pl) Wyrób i sposób testu immunologicznego o podwójnej ścieżce i zredukowanym etapie
GB201115280D0 (en) Antibodies, uses and methods
ZA201308603B (en) Deimmunized serum-binding domains and their use for extending serum half-life
ZA201403492B (en) Antibodies specific for trop-2 and their uses
ZA201306572B (en) Antibody,kit and method for determining amyloid peptides
PL2564202T3 (pl) Sposoby wykrywania przeciwciał przeciw lekowi
EP2542258A4 (en) MONOCLONAL ANTIBODIES DIRECTED AGAINST CD52
SG11201402709WA (en) Method and device for assaying an antigen present on erythrocytes or an antibody binding to an antigen present on erythrocytes
EP2746394A4 (en) ANTIBODY AND COMPOSITION CONTAINING THE SAME
EP2536817A4 (en) IMMUNOASSAY DEVICES FOR THE DETECTION OF ANTIBODIES AND ANTIGENES
EP2707392A4 (en) MONOCLONAL ANTIBODY FOR ACETYLAMANTADINE
IL218438A0 (en) Humanized antibodies specific for hsp65-derived peptide-6 methods and uses thereof